Schreiner, Philipp; Mueller, Nicolas J; Fehr, Jan; Maillard, Michel H; Brand, Stephan; Michetti, Pierre; Schoepfer, Alain; Restellini, Sophie; Vulliemoz, Marianne; Vavricka, Stephan R; Juillerat, Pascal; Rogler, Gerhard; Biedermann, Luc (2020). Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. (In Press). Journal of Crohn's & colitis Oxford University Press 10.1093/ecco-jcc/jjaa132
|
Text
jjaa132.pdf - Published Version Available under License Publisher holds Copyright. Download (319kB) | Preview |
Primary Varicella Zoster virus (VZV) infection results in varicella (chickenpox) while its reactivation results in herpes zoster (HZ; shingles). Patients with Inflammatory Bowel Disease (IBD) are susceptible to complications of primary VZV infection and have an increased risk of HZ. Concerns of VZV and HZ infection in the IBD population has been highlighted by the emergence of JAK-inhibitors and their safety profile in this patient population such as tofacitinib for the treatment of ulcerative colitis (UC). The current pipeline of emerging therapies include novel molecules targeting multiple pathways including JAK/signal transducer and cytokine signalling pathways such as JAK/STAT. Hence VZV and HZ will be increasingly relevant for gastroenterologists treating IBD patients in light of these emerging therapies.
Item Type: |
Journal Article (Review Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology |
UniBE Contributor: |
Juillerat, Pascal |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1873-9946 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Rahel Fuhrer |
Date Deposited: |
22 Dec 2020 17:19 |
Last Modified: |
23 Nov 2023 16:20 |
Publisher DOI: |
10.1093/ecco-jcc/jjaa132 |
PubMed ID: |
32592587 |
BORIS DOI: |
10.7892/boris.149249 |
URI: |
https://boris.unibe.ch/id/eprint/149249 |